8-K: Avinger Reports Improved Financials in Q3 2024, Advances Coronary Product Development

Avinger, Inc. announced improved financial results for the third quarter of 2024, driven by cost reductions and increased gross margins, while also progressing its coronary product development.

Summary

• Avinger reported a revenue of $1.7 million for the third quarter of 2024, consistent with the previous quarter and the same period last year.
• The company's gross margin increased to 26% in Q3 2024, up from 20% in Q2 2024 and 21% in Q3 2023.
• Operating expenses decreased to $4.1 million in Q3 2024, compared to $4.5 million in Q2 2024 and $4.4 million in Q3 2023.
• Avinger's net loss and comprehensive loss improved to $3.7 million in Q3 2024, compared to $4.4 million in Q2 2024 and $4.5 million in Q3 2023.
• Adjusted EBITDA improved to a loss of $3.4 million in Q3 2024, compared to a loss of $3.8 million in Q2 2024 and $3.7 million in Q3 2023.
• The company implemented a cost reduction program in June 2024, reducing headcount by approximately 24%.
• Avinger filed an Investigational Device Exemption (IDE) pre-submission package with the FDA for its coronary CTO-crossing system in September 2024.
• The company anticipates submitting the IDE application in the fourth quarter of 2024.
• Avinger initiated the full commercial launch of its new Pantheris LV device for use in peripheral arteries.
• Avinger is supporting Zylox-Tonbridge's regulatory filings in China, with registration clearance anticipated in 2025.

Sentiment

Score: 7

Explanation: The document shows positive progress in cost reduction, gross margin improvement, and product development, but the company is still operating at a loss and faces risks. The sentiment is cautiously optimistic.

Positives

• The company's cost reduction program has led to a significant decrease in operating expenses.
• Gross margins have improved for the second consecutive quarter.
• Avinger is making progress in its coronary product development with the IDE pre-submission.
• The company is expanding its market reach through its partnership with Zylox-Tonbridge in China.
• Clinical data for the Pantheris SV device shows strong positive outcomes.

Negatives

• Revenue remained flat at $1.7 million compared to the previous quarter and the same period last year.
• The company continues to operate at a loss, with a net loss of $3.7 million in Q3 2024.
• Avinger is dependent on a limited number of products.

Risks

• The company's future performance depends on the successful development and commercialization of new products.
• There are risks associated with obtaining regulatory approvals for its products.
• The adoption of Avinger's products by physicians is not guaranteed.
• The company is dependent on a limited number of products.
• The company is reliant on Zylox-Tonbridge for regulatory approvals and manufacturing in China.

Future Outlook

Avinger anticipates submitting its IDE application for its coronary CTO-crossing system in the fourth quarter of 2024 and expects Zylox to complete its full manufacturing scale-up by mid-2025. The company also expects to expand to 10 or more clinical sites before study initiation.

Management Comments

• In the third quarter, we began to see the impact of recent initiatives to streamline costs, enhance operational efficiency, and intensify our focus on developing our coronary platform, stated Jeff Soinski, Avinger's President and CEO.
• Our OCT image-guided approach aims to provide superior, streamlined, and more predictable clinical results, positioning Avinger to transform this market for both physicians and patients.
• We are excited about the strides Zylox is making in expanding access to our proprietary image-guided products for the estimated 50 million people in China affected by peripheral artery disease, Soinski continued.

Industry Context

Avinger is operating in the competitive medical device industry, focusing on vascular disease treatment. The company's focus on image-guided technology and its expansion into the coronary market aligns with the industry's trend towards minimally invasive procedures and advanced imaging techniques. The partnership with Zylox-Tonbridge is a strategic move to tap into the large Chinese market.

Comparison to Industry Standards

• Avinger's gross margin of 26% is a positive sign, but it is still lower than some established medical device companies, which often have gross margins above 60%.
• The company's focus on coronary CTO-crossing is a niche area, and its success will depend on the clinical outcomes and adoption by physicians.
• Companies like Medtronic and Abbott are major players in the vascular device market, and Avinger will need to demonstrate a clear competitive advantage to gain market share.
• The clinical data from the IMAGE-BTK study is promising, but further studies and real-world evidence will be needed to validate the long-term efficacy of the Pantheris SV device.
• The regulatory approval process in China can be lengthy and complex, and Avinger's partnership with Zylox-Tonbridge will be crucial for navigating this process.

Management Changes

Stakeholder Impact

• Shareholders may view the improved financial results and progress in product development positively.
• Employees may be impacted by the cost reduction program, which included a 24% reduction in headcount.
• Physicians may benefit from the new Pantheris LV device and the potential for improved outcomes with the coronary CTO-crossing system.
• Patients may benefit from the new technologies and treatments for vascular disease.
• Zylox-Tonbridge is a key partner and will be impacted by the success of the regulatory filings and manufacturing scale-up in China.

Next Steps

• Avinger will submit its IDE application for its coronary CTO-crossing system to the FDA in the fourth quarter of 2024.
• The company will continue to support Zylox-Tonbridge's regulatory filings in China.
• Avinger will expand to 10 or more clinical sites before study initiation.
• Zylox-Tonbridge will complete its full manufacturing scale-up for Avinger devices by mid-2025.

Key Dates

Keywords

Avinger, medical devices, vascular disease, atherectomy, OCT, coronary artery disease, peripheral artery disease, IDE, FDA, Zylox-Tonbridge, China, gross margin, EBITDA